Retractable Technologies, Inc. (RVP) P/E Ratio History
Deep ValueTrading at -1.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2003–2022
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Retractable Technologies, Inc. (RVP) trades at a price-to-earnings ratio of -1.6x, with a stock price of $0.70 and trailing twelve-month earnings per share of $-0.21.
The current P/E is 108% below its 5-year average of 19.5x. Over the past five years, RVP's P/E has ranged from a low of 2.2x to a high of 118.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, RVP trades at a 107% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, RVP trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RVP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RVP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
RVP P/E vs Peers
Drug delivery and infusion consumables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 32.9 | - | +5% | |
| $233M | 21.0Lowest | 6.12 | -12% | |
| $1B | 43.3 | 4.30 | +18% | |
| $56B | 26.6 | 1.61Best | -1% | |
| $13B | 21.0 | 2.94 | +53% | |
| $10B | 25.8 | 8.18 | +7% | |
| $187M | 21.9 | 1.79 | +345%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
RVP Historical P/E Data (2003–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Dec 31 2022 | $1.64 | $0.14 | 11.7x | -35% |
| FY2022 Q3 | Sep 30 2022 | $1.98 | $0.89 | 2.2x | -88% |
| FY2022 Q2 | - | $3.83 | $0.92 | 4.2x | -77% |
| FY2022 Q1 | - | $4.75 | $1.34 | 3.5x | -80% |
| FY2021 Q4 | Dec 31 2021 | $6.93 | $1.63 | 4.3x | -77% |
| FY2021 Q3 | - | $11.03 | $1.36 | 8.1x | -55% |
| FY2021 Q2 | Jun 30 2021 | $11.56 | $1.50 | 7.7x | -57% |
| FY2021 Q1 | Mar 31 2021 | $12.82 | $1.30 | 9.9x | -46% |
| FY2020 Q4 | - | $10.74 | $0.78 | 13.7x | -24% |
| FY2020 Q3 | Sep 30 2020 | $6.66 | $0.50 | 13.3x | -27% |
| FY2020 Q2 | - | $7.02 | $0.20 | 34.8x | +92% |
| FY2020 Q1 | - | $1.56 | $0.10 | 15.4x | -15% |
| FY2019 Q4 | - | $1.50 | $0.09 | 16.1x | -11% |
| FY2019 Q3 | Sep 30 2019 | $1.15 | $0.03 | 36.6x | +102% |
| FY2016 Q1 | - | $2.15 | $0.14 | 15.8x | -13% |
| FY2015 Q4 | - | $3.10 | $0.13 | 23.0x | +27% |
| FY2015 Q3 | Sep 30 2015 | $3.62 | $0.19 | 18.8x | +4% |
| FY2015 Q2 | - | $3.80 | $0.21 | 18.4x | +2% |
| FY2011 Q4 | Dec 31 2011 | $1.18 | $0.01 | 118.0x | +551% |
| FY2011 Q3 | Sep 30 2011 | $1.35 | $0.10 | 13.9x | -23% |
| FY2011 Q2 | - | $1.54 | $0.33 | 4.7x | -74% |
| FY2011 Q1 | - | $1.65 | $0.19 | 8.8x | -51% |
| FY2010 Q4 | Dec 31 2010 | $1.75 | $0.04 | 42.1x | +132% |
| FY2010 Q3 | - | $1.57 | $0.10 | 15.2x | -16% |
| FY2005 Q2 | - | $2.70 | $1.82 | 1.5x | -92% |
| FY2005 Q1 | - | $4.00 | $2.09 | 1.9x | -89% |
| FY2004 Q4 | Dec 31 2004 | $4.60 | $2.02 | 2.3x | -87% |
| FY2004 Q3 | - | $4.54 | $1.96 | 2.3x | -87% |
| FY2004 Q1 | Mar 31 2004 | $6.28 | $0.17 | 36.1x | +99% |
| FY2003 Q4 | Dec 31 2003 | $6.02 | $0.24 | 25.4x | +40% |
| FY2003 Q3 | - | $6.11 | $0.28 | 21.5x | +19% |
| FY2003 Q2 | Jun 30 2003 | $8.49 | $0.30 | 28.8x | +59% |
Average P/E for displayed period: 18.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RVP — Frequently Asked Questions
Quick answers to the most common questions about buying RVP stock.
What is RVP's P/E ratio?
Retractable Technologies, Inc. (RVP) trailing twelve-month P/E ratio is -1.6x, based on TTM diluted EPS of $-0.21. The 5-year average P/E is 19.5x and the historical range spans 2.2x to 118.0x.
Is RVP stock overvalued or undervalued?
RVP trades at -1.6x P/E, below its 5-year average of 19.5x. At the 0th percentile of its historical range (2.2x–118.0x), the stock is priced at a discount to its own history.
Is RVP stock expensive?
No, RVP is not expensive on a historical basis. The current P/E of -1.6x is below the 5-year average of 19.5x and sits at the 0th percentile of its valuation range.
What is RVP's historical P/E range?
Over the past 5 years, RVP's P/E ratio has ranged from 2.2x to 118.0x, with a median of 13.9x and an average of 19.5x. The current P/E of -1.6x places the stock at the 0th percentile of this range. Full historical data spans 2003–2022.
How does RVP's P/E compare to the S&P 500?
RVP trades at -1.6x P/E versus the S&P 500 median of 25.1x. The 106% discount to the market suggests lower growth expectations or perceived higher risk.
How does RVP's valuation compare to Healthcare peers?
Retractable Technologies, Inc. P/E of -1.6x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is RVP's PEG ratio?
RVP PEG ratio is N/A, based on a P/E of -1.6x and EPS growth of -7.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is RVP's earnings yield?
RVP earnings yield is N/A, the inverse of its -1.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.